Securities Fraud Class Action Launched Against Beta Bionics
A securities fraud class action has been launched against Beta Bionics. The headline cites a November 3, 2026 deadline.
Related stories
India Supreme Court Dismisses Government Challenge to Vedanta Arbitration Awards
The Supreme Court dismissed the Union government’s challenge to a Delhi High Court order allowing Vedanta and Ravva Oil (Singapore) to enforce foreign arbitration awards involving
M impact | REGULATION | Nov 02, 2026, 02:36 PM UTC
China Rolls Out Measures to Support Struggling Stocks
China rolled out support measures to aid struggling stocks. The alert says the PBOC conducted swaps but is truncated before further details.
M impact | REGULATION | Nov 02, 2026, 02:36 PM UTC
Strategy: Offers Up To $4.13 Bln Of 10.00% Series A Perpetual Stride Preferred Stock - SEC Filing
L impact | REGULATION | Nov 02, 2026, 02:35 PM UTC
Roche Gets FDA Clearance for cobas eplex RP3 Respiratory Test
Roche obtained FDA clearance for its cobas eplex RP3 respiratory test.
L impact | REGULATION | Nov 02, 2026, 02:31 PM UTC
DEA Begins Issuing Federal Registrations to State-Licensed Dispensaries
The DEA has begun the initial issuance of federal registrations to state-licensed dispensaries, according to the headline.
M impact | REGULATION | Nov 02, 2026, 02:19 PM UTC
FDA Grants Tentative Approval for Dr. Reddy’s Lenacapavir
The U.S. FDA granted tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir.
M impact | REGULATION | Nov 02, 2026, 02:15 PM UTC